Iridex Receives European Patent on MicroPulse Technology

Iridex announced the grant of the European Patent 'EP 3009093,' titled "Laser System with Short Pulse Characteristics and its Methods of Use.” This patent protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields for 'technology that enhances safe and effective laser treatments.' Iridex is the exclusive provider of MicroPulse devices that utilize the patented technology. 

The patented technology delivers a laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications. By employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage, Iridex noted in a news release.

"This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," David Bruce, President and CEO of Iridex Corporation, said in the news release.